Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304740 | 0.86 | PTGS2 (0.50) | PTGS2DHFRALDH1A1TSHRTDP1 | |
| SCHEMBL1530698 | 0.80 | HSD17B10 (0.47) | PTGS2ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL11513611 | 0.80 | DHFR (0.39) | PTGS2DHFRALDH1A1TSHRTDP1 | |
| SCHEMBL14112766 | 0.78 | ALOX15 (0.44) | PTGS2ALDH1A1TSHRTDP1CA2 | |
| SCHEMBL7968046 | 0.78 | PTGS2 (0.41) | PTGS2DHFRALDH1A1TSHRTDP1 | |
| SCHEMBL12706039 | 0.78 | RARG (0.39) | PTGS2DHFRALDH1A1TSHRTDP1 | |
| SCHEMBL12678876 | 0.77 | PTGS2 (0.40) | PTGS2DHFRALDH1A1TSHRTDP1 | |
| SCHEMBL699612 | 0.77 | DHFR (0.37) | PTGS2DHFRALDH1A1TSHRTDP1 | |
| SCHEMBL5946205 | 0.75 | HSD17B10 (0.50) | ALDH1A1TSHRPOLBL3MBTL1CA2 | |
| SCHEMBL28939024 | 0.74 | PTGDR2 (0.37) | PTGS2ALDH1A1TSHRTDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8734777-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-8734777-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2014-05-27 | — | — | US | disclosed |
| EP-2385039-B1 | 2-Iminoisoindolinone derivatives as thrombin receptor antagonists | EISAI R&D MAN CO LTD (JP) | 2014-03-12 | — | — | EP | disclosed |
| US-20130209397-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130209397-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2013-08-15 | — | — | US | disclosed |
| US-8178547-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178547-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-05-15 | — | — | US | disclosed |
| WO-2012020037-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| EP-1614680-B1 | Process for preparing 2-iminopyrrolidine derivatives | EISAI R&D MAN CO LTD (JP) | 2011-12-21 | — | — | EP | disclosed |
| EP-1391451-B1 | 2-IMINOPYRROLIDINE DERIVATES | EISAI R&D MAN CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| EP-2385039-A1 | 2-Iminoisoindolinone derivatives as thrombin receptor antagonists | Eisai R&D Management Co., Ltd. (JP) | 2011-11-09 | — | — | EP | disclosed |
| WO-2010072598-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| US-7244730-B2 | 2-iminopyrrolidine derivatives | EISAI CO., LTD (JP) | 2007-07-17 | — | — | US | disclosed |
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1391451-A1 | 2-IMINOPYRROLIDINE DERIVATES | Eisai Co., Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245592-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | PTGS2 1313/4885DHFR 1264/4885ALDH1A1 443/4885 |
| US-20050004204-A1 | 2-Iminopyrrolidine derivatives | H1-2, H1-3, H1-0 | PTGS2 1298/4885DHFR 1262/4885ALDH1A1 437/4885 |
| US-20130209397-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, MAVS | PTGS2 1860/4885DHFR 936/4885ALDH1A1 540/4885 |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RFC1, RRP1B, RRBP1 | PTGS2 4240/4885DHFR 1905/4885ALDH1A1 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.